Sorafenib vs Observation Following Radical Metastasectomy for Clear-Cell Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-Cell Renal Cell Carcinoma: Results From the Phase 2 Randomized Open-Label RESORT Study
Eur Urol Oncol 2019 Sep 18;[EPub Ahead of Print], G Procopio, G Apollonio, F Cognetti, R Miceli, M Milella, A Mosca, VE Chiuri, A Bearz, F Morelli, C Ortega, F Atzori, M Donini, R Ratta, A Raimondi, M Claps, A Martinetti, U Capitanio, FG de Braud, V Cappelletti, E VerzoniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.